Oral and pulmonary delivery of thioether-bridged angiotensin-(1-7)

Peptides

Volumn 31, Issue 5, 2010, Pages 893-898

  de Vries, Louwe ^a   Reitzema Klein, Christina E ^a   Meter Arkema, Anita ^a,b   van Dam, Annie ^a   Rink, Rick ^a   Moll, Gert N ^a   Akanbi, Marijke Haas Jimoh ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF ILORIN   (Nigeria)

Author keywords

Angiotensin; Cyclic; Lanthionine; Stability; Therapeutic peptide; Thioether

Indexed keywords

ANGIOTENSIN DERIVATIVE; ANGIOTENSIN[1-7]; PROTEINASE; THIOETHER ANGIOTENSIN[1-7]; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; DRUG UPTAKE; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SWINE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANGIOTENSIN I; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DRUG ADMINISTRATION ROUTES; MALE; MASS SPECTROMETRY; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TRACHEA;

EID: 77951254784     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.02.015     Document Type: Article

References (35)

1. Agarwal S., Boddu S.H., Jain R., Samanta S., Pal D., Mitra A.K. Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor. Int J Pharm 2008, 359:7-14.
2. Allred A.J., Diz D.I., Ferrario C.M., Chappell M.C. Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. Am J Physiol Renal Physiol 2000, 279:F841-850.
3. Benter I.F., Ferrario C.M., Morris M., Diz D.I. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 1995, 269:H313-H319.
4. Chan L.M.S., Lowes S., Hirst B.H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004, 21:25-51.
5. Ebermann L., Spillmann F., Sidiropoulos M., Escher F., Heringer-Walther S., Schultheiss H.P., et al. The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. Eur J Pharmacol 2008, 590:276-280.
6. Flinterman M., Farzaneh F., Habib N., Malik F., Gäken J., Tavassoli M. Delivery of therapeutic proteins as secretable TAT fusion products. Mol Ther 2009, 17:334-342.
7. Heringer-Walther S., Eckert K., Schumacher S.M., Uharek L., Wulf-Goldenberg A., Gembardt F., et al. Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica 2009, 94:857-860.
8. Kluskens L.D., Kuipers A., Rink R., de Boef E., Fekken S., Driessen A.J., et al. Post-translational modification of therapeutic peptides by NisB, the dehydratase of the lantibiotic nisin. Biochemistry 2005, 44:12827-12834.
9. Kluskens L.D., Nelemans S.A., Rink R., de Vries L., Meter-Arkema A., Wang Y., et al. Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J Pharmacol Exp Ther 2009, 328:849-854.
10. Kucharewicz I., Pawlak R., Matys T., Pawlak D., Buczko W. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension 2002, 40:774-779.
11. Kuipers A., de Boef E., Rink R., Fekken S., Kluskens L.D., Driessen A.J., et al. NisT, the transporter of the lantibiotic nisin, can transport fully modified, dehydrated, and unmodified prenisin and fusions of the leader peptide with non-lantibiotic peptides. J Biol Chem 2004, 279:22176-22182.
12. Kuipers A., Wierenga J., Rink R., Kluskens L.D., Driessen A.J., Kuipers O.P., et al. Sec-mediated transport of posttranslationally dehydrated peptides in Lactococcus lactis. Appl Environ Microbiol 2006, 72:7626-7633.
13. Kuipers A., Meijer-Wierenga J., Rink R., Kluskens L.D., Moll G.N. Mechanistic dissection of the enzyme complexes involved in biosynthesis of lacticin 3147 and nisin. Appl Environ Microbiol 2008, 74:6591-6597.
14. Kuipers A., Rink R., Moll G.N. Translocation of a thioether-bridged azurin peptide fragment via the sec pathway in Lactococcus lactis. Appl Environ Microbiol 2009, 75:3800-3802.
15. Langeveld B., van Gilst W.H., Tio R.A., Zijlstra F., Roks A.J.M. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 2005, 45:138-141.
16. Loot A.E., Roks A.J., Henning R.H., Tio R.A., Suurmeijer A.J., Boomsma F., et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002, 105:1548-1550.
17. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
18. Lula I., Denadai A.L., Resende J.M., de Sousa F.B., de Lima G.F., Pilo-Veloso D., et al. Study of angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. Peptides 2007, 28:2199-2210.
19. Morishita M., Peppas N.A. Is the oral route possible for peptide and protein drug delivery?. Drug Discov Today 2006, 11:905-910.
20. Menon J., Soto-Pantoja D.R., Callahan M.F., Cline J.M., Ferrario C.M., Tallant E.A., et al. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res 2007, 67:2809-2815.
21. Pereira R.M., Dos Santos R.A., Teixeira M.M., Leite V.H., Costa L.P., da Costa Dias F.L., et al. The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7). J Hepatol 2007, 46:674-681.
22. Petrus A.K., Fairchild T.J., Doyle R.P. Traveling the vitamin B12 pathway: oral delivery of protein and peptide drugs. Angew Chem Int Ed Engl 2009, 48:1022-1028.
23. Prego C., Torres D., Alonso M.J. Chitosan nanocapsules as carriers for oral peptide delivery: effect of chitosan molecular weight and type of salt on the in vitro behaviour and in vivo effectiveness. J Nanosci Nanotechnol 2006, 6:2921-2928.
24. Qian F., Mathias N., Moench P., Chi C., Desikan S., Hussain M., et al. Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117. Int J Pharm 2009, 366:218-220.
25. Rink R., Kuipers A., de Boef E., Leenhouts K.J., Driessen A.J., Moll G.N., et al. Lantibiotic structures as guidelines for the design of peptides that can be modified by lantibiotic enzymes. Biochemistry 2005, 44:8873-8882.
26. Rink R., Kluskens L.D., Kuipers A., Driessen A.J., Kuipers O.P., Moll G.N. NisC, the cyclase of the lantibiotic nisin, can catalyze cyclization of designed nonlantibiotic peptides. Biochemistry 2007, 46:13179-13189.
27. Rodgers K.E., Xiong S., diZerega G.S. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol 2002, 49:403-411.
28. Rodgers K.E., Oliver J., diZerega G.S. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol 2006, 57:559-568.
29. Santos R.A., Campagnole-Santos M.J., Andrade S.P. Angiotensin-(1-7): an update. Regul Pept 2000, 91:45-62.
30. Santos R.A., Ferreira A.J., Nadu A.P., Braga A.N., de Almeida A.P., Campagnole-Santos M.J., et al. Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics 2004, 17:292-299.
31. Santos R.A., Frezard F., Ferreira A.J. Angiotensin-(1-7): blood, heart, and blood vessels. Curr Med Chem Cardiovasc Hematol Agents 2005, 3:383-391.
32. Santos R.A., Ferreira A.J. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc Drug Rev 2006, 24:239-246.
33. Shoyele S.A., Slowey A. Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int J Pharm 2006, 314:1-8.
34. Yamada K., Iyer S.N., Chapell M.C., Ganten D., Ferrario C.M. Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension 1998, 32:496-502.
35. Youn Y.S., Chae S.Y., Lee S., Kwon M.J., Shin H.J., Lee K.C. Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation. Eur J Pharm Biopharm 2008, 68:667-675.